Results demonstrated reduced motor-neuron hyperexcitability that was generally consistent with the signal previously observed in healthy volunteers Safety and tolerabilityResults demonstrated reduced motor-neuron hyperexcitability that was generally consistent with the signal previously observed in healthy volunteers Safety and tolerability

QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener

Results demonstrated reduced motor-neuron hyperexcitability that was generally consistent with the signal previously observed in healthy volunteers

Safety and tolerability profile consistent with previously reported results for QRL-101

QurAlis intends to advance QRL-101 into Phase 2 proof-of-concept clinical trials as a potentially best-in-class treatment for both DEE and ALS

CAMBRIDGE, Mass.–(BUSINESS WIRE)–QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced topline data from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101 in people living with amyotrophic lateral sclerosis (ALS). Results from this study demonstrate for the first time, evidence of target engagement with a selective Kv7.2/7.3 ion channel opener in ALS patients.

Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of both neuronal excitability and membrane potential. QRL-101 is a potentially best-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS, which occurs in both sporadic and genetic forms of ALS, with the majority caused by the mis-splicing of the KCNQ2 gene in the pre-mRNA. Kv7 is a clinically validated target to regulate the hyperexcitable state in epilepsy; and QurAlis is also advancing QRL-101 in developmental and epileptic encephalopathies (DEE). Preclinical studies have demonstrated that QRL-101 is more potent and exhibits the potential for fewer clinical adverse events than ezogabine, a less selective, first-generation, Kv7.2/7.3 channel opener.

“This is the first time we are seeing target engagement of QRL-101 in ALS patients with a biomarker which predicts survival in ALS. This is extremely encouraging as new research published in Nature Neuroscience provides additional evidence that loss of TDP-43 function drives mis-splicing of the KCNQ2 potassium channel, producing a dysfunctional isoform that disrupts neuronal excitability in ALS and frontotemporal dementia, further validating this disease mechanism,” said Kasper Roet, Ph.D., CEO and co-founder of QurAlis. “QurAlis’ co-founders and collaborators had previously demonstrated that loss of Kv7.2/7.3 leads to motor neuron death and we are excited by these data which confirm that QRL-101 has the potential to provide a therapeutic effect for ALS patients. We look forward to advancing the clinical program for QRL-101 in ALS, as well as in epilepsy, so that we can rapidly bring a much-needed precision medicine option to multiple patient populations.”

Results showed reduced motor-neuron hyperexcitability compared to placebo, with a more robust response being observed in patients with higher exposure to QRL-101. In addition, there was a consistent, expected directional change across multiple measures including strength-duration time constant (SDTC), rheobase, and eight of the nine additional measures evaluated as part of the motor nerve excitability threshold tracking (mNETT) assessment. These results are generally consistent with the signal previously observed in healthy volunteers (QRL-101-05, NCT06681441) across these measures.

Results also demonstrated that the pharmacokinetic (PK), safety, and tolerability profile of QRL-101 was consistent with previously reported study results evaluating QRL-101. There were no serious adverse events or discontinuations due to adverse events reported observed in the study.

QRL-101-04 (NCT06714396) was a Phase 1 PoM single-dose, placebo-controlled clinical trial designed to evaluate the safety and tolerability of QRL-101 in people living with ALS. QRL-101-04 enrolled 12 participants with ALS and evaluated the impact of QRL-101 on mNETT across three different dose levels, randomized 3:1 between QRL-101 and placebo. The primary endpoint of the study was exploration of the PK and pharmacodynamic relationship of QRL-101 and was not powered to demonstrate a statistically significant difference between QRL-101 and placebo arms.

More information about the QRL-101-04 clinical trial can be found at www.clinicaltrials.gov.

About QurAlis Corporation

At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.

Contacts

Kathy Vincent

kathy.vincent@quralis.com
310-403-8951

Market Opportunity
1 Logo
1 Price(1)
$0.01334
$0.01334$0.01334
+39.61%
USD
1 (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security

Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security

BitcoinWorld Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security Ever wondered why withdrawing your staked Ethereum (ETH) isn’t an instant process? It’s a question that often sparks debate within the crypto community. Ethereum founder Vitalik Buterin recently stepped forward to defend the network’s approximately 45-day ETH unstaking period, asserting its crucial role in safeguarding the network’s integrity. This lengthy waiting time, while sometimes seen as an inconvenience, is a deliberate design choice with profound implications for security. Why is the ETH Unstaking Period a Vital Security Measure? Vitalik Buterin’s defense comes amidst comparisons to other networks, like Solana, which boast significantly shorter unstaking times. He drew a compelling parallel to military operations, explaining that an army cannot function effectively if its soldiers can simply abandon their posts at a moment’s notice. Similarly, a blockchain network requires a stable and committed validator set to maintain its security. The current ETH unstaking period isn’t merely an arbitrary delay. It acts as a critical buffer, providing the network with sufficient time to detect and respond to potential malicious activities. If validators could instantly exit, it would open doors for sophisticated attacks, jeopardizing the entire system. Currently, Ethereum boasts over one million active validators, collectively staking approximately 35.6 million ETH, representing about 30% of the total supply. This massive commitment underpins the network’s robust security model, and the unstaking period helps preserve this stability. Network Security: Ethereum’s Paramount Concern A shorter ETH unstaking period might seem appealing for liquidity, but it introduces significant risks. Imagine a scenario where a large number of validators, potentially colluding, could quickly withdraw their stake after committing a malicious act. Without a substantial delay, the network would have limited time to penalize them or mitigate the damage. This “exit queue” mechanism is designed to prevent sudden validator exodus, which could lead to: Reduced decentralization: A rapid drop in active validators could concentrate power among fewer participants. Increased vulnerability to attacks: A smaller, less stable validator set is easier to compromise. Network instability: Frequent and unpredictable changes in validator numbers can lead to performance issues and consensus failures. Therefore, the extended period is not a bug; it’s a feature. It’s a calculated trade-off between immediate liquidity for stakers and the foundational security of the entire Ethereum ecosystem. Ethereum vs. Solana: Different Approaches to Unstaking When discussing the ETH unstaking period, many point to networks like Solana, which offers a much quicker two-day unstaking process. While this might seem like an advantage for stakers seeking rapid access to their funds, it reflects fundamental differences in network architecture and security philosophies. Solana’s design prioritizes speed and immediate liquidity, often relying on different consensus mechanisms and validator economics to manage security risks. Ethereum, on the other hand, with its proof-of-stake evolution from proof-of-work, has adopted a more cautious approach to ensure its transition and long-term stability are uncompromised. Each network makes design choices based on its unique goals and threat models. Ethereum’s substantial value and its role as a foundational layer for countless dApps necessitate an extremely robust security posture, making the current unstaking duration a deliberate and necessary component. What Does the ETH Unstaking Period Mean for Stakers? For individuals and institutions staking ETH, understanding the ETH unstaking period is crucial for managing expectations and investment strategies. It means that while staking offers attractive rewards, it also comes with a commitment to the network’s long-term health. Here are key considerations for stakers: Liquidity Planning: Stakers should view their staked ETH as a longer-term commitment, not immediately liquid capital. Risk Management: The delay inherently reduces the ability to react quickly to market volatility with staked assets. Network Contribution: By participating, stakers contribute directly to the security and decentralization of Ethereum, reinforcing its value proposition. While the current waiting period may not be “optimal” in every sense, as Buterin acknowledged, simply shortening it without addressing the underlying security implications would be a dangerous gamble for the network’s reliability. In conclusion, Vitalik Buterin’s defense of the lengthy ETH unstaking period underscores a fundamental principle: network security cannot be compromised for the sake of convenience. It is a vital mechanism that protects Ethereum’s integrity, ensuring its stability and trustworthiness as a leading blockchain platform. This deliberate design choice, while requiring patience from stakers, ultimately fortifies the entire ecosystem against potential threats, paving the way for a more secure and reliable decentralized future. Frequently Asked Questions (FAQs) Q1: What is the main reason for Ethereum’s long unstaking period? A1: The primary reason is network security. A lengthy ETH unstaking period prevents malicious actors from quickly withdrawing their stake after an attack, giving the network time to detect and penalize them, thus maintaining stability and integrity. Q2: How long is the current ETH unstaking period? A2: The current ETH unstaking period is approximately 45 days. This duration can fluctuate based on network conditions and the number of validators in the exit queue. Q3: How does Ethereum’s unstaking period compare to other blockchains? A3: Ethereum’s unstaking period is notably longer than some other networks, such as Solana, which has a two-day period. This difference reflects varying network architectures and security priorities. Q4: Does the unstaking period affect ETH stakers? A4: Yes, it means stakers need to plan their liquidity carefully, as their staked ETH is not immediately accessible. It encourages a longer-term commitment to the network, aligning staker interests with Ethereum’s stability. Q5: Could the ETH unstaking period be shortened in the future? A5: While Vitalik Buterin acknowledged the current period might not be “optimal,” any significant shortening would likely require extensive research and network upgrades to ensure security isn’t compromised. For now, the focus remains on maintaining robust network defenses. Found this article insightful? Share it with your friends and fellow crypto enthusiasts on social media to spread awareness about the critical role of the ETH unstaking period in Ethereum’s security! To learn more about the latest Ethereum trends, explore our article on key developments shaping Ethereum’s institutional adoption. This post Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security first appeared on BitcoinWorld.
Share
Coinstats2025/09/18 15:30
Shiba Inu Price Forecast: Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale

Shiba Inu Price Forecast: Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale

While Shiba Inu (SHIB) continues to build its ecosystem and PEPE holds onto its viral roots, a new contender, Layer […] The post Shiba Inu Price Forecast: Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale appeared first on Coindoo.
Share
Coindoo2025/09/18 01:13
The U.S. Financial Accounting Standards Board plans to study in 2026 whether crypto assets such as stablecoins can be classified as cash equivalents.

The U.S. Financial Accounting Standards Board plans to study in 2026 whether crypto assets such as stablecoins can be classified as cash equivalents.

PANews reported on December 31 that the Financial Accounting Standards Board (FASB) plans to study in 2026 whether certain crypto assets can be classified as cash
Share
PANews2025/12/31 16:50